Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]
I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval of Provenge, Zytiga, Jevtana, Xtandi and hopefully in the near future Radium-223 Dichloride (Alpharadin) we have many new treatment options [...]
One of the constant complaints I hear fro men with advanced prostate cancer that has become castrate resistant about Provenge (sipuleucel-T) is that the anticipated increase in overall survival is only 4.1 months and given the cost of $93,000 for the three infusions many men feel that cost does not justify the survival benefit. My [...]
On September 27th Dendreon announced that it has enrolled and started its first patient with metastatic advanced prostate cancer that is castrate resistanr in a European Union based clinical trial of Provenge. Finally, men in the EU can hope that in the near future that Provenge could become available to them. The trial is hoped [...]
The summer is coming to a close and I am back, ready to again take on the world. I had the fantastic opportunity of spending almost two weeks in Alaska, a land that is so different from the lower 48. I have to say that I have a new found respect for those individuals who [...]